Structure and Expression of Fibulin-2, a Novel Extracellular Matrix Protein with Multiple EGF-like Repeats and Consensus Motifs for Calcium Binding

Te-Cheng Pan,* Takako Sasaki,† Rui-Zhu Zhang,* Reinhard Fässler,‡ Rupert Timpl,‡ and Mon-Li Chu*

*Departments of Biochemistry and Molecular Biology and Dermatology, Jefferson Institute of Molecular Medicine, Jefferson Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania 19107-5541; and ‡Max-Planck-Institut für Biochemie, D-82152 Martinsried, Federal Republic of Germany

Abstract. A new protein, fibulin-2, was predicted from sequence analysis of cDNA clones obtained from a mouse fibroblast library. This protein consists of a 1195-residue polypeptide preceded by a 26-residue signal peptide. The COOH-terminal region of 787 amino acids contained three anaphylatoxin-related segments (domain I), 11 EGF-like repeats (domain II), 10 of which had a consensus motif for calcium-binding, and a 115-residue globular domain III. Except for two additional EGF-like repeats, this COOH-terminal region showed 43% sequence identity with the previously described fibulin-1 (BM-90). The NH2-terminal 408 residues, unique to fibulin-2, showed no sequence homology to other known proteins and presumably form two additional domains that differ in their cysteine content. Recombinant fibulin-2 was produced and secreted by human cell clones as a disulfide-bonded trimer. Rotary shadowing visualized the protein as three 40-45 nm long rods which are connected at one end in a globe-like structure. No significant immunological cross-reaction could be detected between fibulin-1 and fibulin-2. Production of the fibulin-2 was demonstrated by Northern blots and radioimmunoassay in fibroblasts but not in several tumour cell lines. Together with the observation that the serum level of fibulin-2 is 1,000-fold lower than that of fibulin-1, the data indicate that these two isoforms are not always coordinately expressed. This is also suggested by Northern blots of tissue mRNAs and by immunofluorescence localizations using mouse tissues. The latter studies also demonstrated an extracellular localization for fibulin-2 in basement membranes and other connective tissue compartments.

Most extracellular matrix proteins have mosaic structures (Bork, 1991; Engel, 1993) and frequently possess ~50-residue repeats homologous to EGF. These repeats usually contain three or, as with laminin and perlecain, four disulfide bridges stabilizing a tightly folded structure (Baron et al., 1991; Selander-Sunnerhagen et al., 1992). As shown for laminin (Beck et al., 1990; Engel, 1993) and tenascin (Spring et al., 1989), such repeats can form rodlike structures if they occur in multiple consecutive copies, and thus may serve as structural or spacing elements. An additional function is their binding of calcium, indicated by a special sequence motif identified so far in more than 150 EGF-like repeats (Rees et al., 1988; Persson et al., 1989; Handford et al., 1990), suggesting that modulation of binding can occur in the extracellular space. Of particular interest, although less well studied, is the participation of EGF-like repeats in the interactions with extracellular matrix proteins and cellular receptors. This was shown for a single repeat of the laminin B2 chain which binds nidogen (Mayer et al., 1993) while other repeats may be responsible for laminin's mitogenic activity (Panayotou et al., 1989). The biological relevance of these structures has been emphasized by mutations found in fibrillin that cause Marfan syndrome (Dietz et al., 1991, 1992; Lee et al., 1991) and mutations in the neurogenic Drosophila protein notch which are lethal (Kelley et al., 1987).

Recent cDNA sequence analysis of human and mouse extracellular proteins nidogen (Mann et al., 1989) and fibulin/BM-90 (Argarves et al., 1990; Pan et al., 1993), and is especially abundant in the microfibrillar protein fibrillin (Lee et al., 1991; Maslen et al., 1991). Studies with coagulation factors have shown that calcium-binding affinities of such repeats are in the millimolar range (Rees et al., 1988; Persson et al., 1989; Handford et al., 1990), suggesting that modulation of binding can occur in the extracellular space. Of particular interest, although less well studied, is the participation of EGF-like repeats in the interactions with extracellular matrix proteins and cellular receptors. This was shown for a single repeat of the laminin B2 chain which binds nidogen (Mayer et al., 1993) while other repeats may be responsible for laminin's mitogenic activity (Panayotou et al., 1989). The biological relevance of these structures has been emphasized by mutations found in fibrillin that cause Marfan syndrome (Dietz et al., 1991, 1992; Lee et al., 1991) and mutations in the neurogenic Drosophila protein notch which are lethal (Kelley et al., 1987).
fibulin-1 (Arggraves et al., 1990; Pan et al., 1993) has shown that the major central domain of the protein consists of nine EGF-like repeats, with eight of them possessing the consensus sequence for calcium binding. This protein was originally described as integrin-binding fibulin from human placenta (Arggraves et al., 1989) and as BM-90 from a basement membrane-producing mouse tumor (Kluge et al., 1990). Preliminary electronmicroscopical data suggested a rodlike structure for fibulin-1 (Kluge, 1990), consistent with the sequence predictions. Calcium binding to fibulin-1 is apparently required to mediate its binding to laminin and nidogen (Pan et al., 1993). Other interactions were observed with fibronectin and with fibulin-1 itself but were not dependent on calcium (Balbona et al., 1992; Pan et al., 1993). Little else is known about possible functions except that fibulin-1 shows prominent expression at sites of epithelial endothelial-mesenchymal transitions during embryonic development (Spence et al., 1992; Zhang et al., 1993).

In our sequence analysis of mouse fibulin-1 (Pan et al., 1993), several similar cDNA clones were obtained that suggested the existence of a second isoform. Completion of the sequence of these clones now predicts a novel and longer protein, fibulin-2. This also suggests that both isoforms are members of a new family of genetically related extracellular matrix proteins. Recombinant expression of fibulin-2 demonstrated its assembly into oligomers consisting of three identical subunits, while fibulin-1 consists of monomers. Additional differences between the fibulin isoforms were noted in their expression patterns in cultured cells and tissues, suggesting that they may have different biological functions.

Materials and Methods

Isolation and Sequencing of cDNA Clones

A mouse fibroblast cDNA library was prepared from 5 μg of poly A-enriched RNA using reagents from a cDNA synthesis kit (Pharmacia Inc., Piscataway, NJ) and a ZAP II cloning kit (Stratagene Inc., La Jolla, CA). The unamplified cDNA library (~5 × 10^6 clones) was screened with a 650-bp human fibulin-1 cDNA prepared by the polymerase chain reaction based on published sequences (Arggraves et al., 1990; Pan et al., 1993). The screening was performed under low stringency hybridization conditions (6 × SSC at 55°C) (Sambrook et al., 1989). Several positive clones with insert sizes from 1.2 to 4.4 kb were characterized by dideoxynucleotide DNA sequencing (Sanger et al., 1977). The DNA sequence was compared to sequences in the databank using the FASTA computer program (Pearson and Lipman, 1988).

Northern Blot Analysis

Total RNA was prepared from mouse fibroblasts using the acid guanidine thiocyanate/phenol/chloroform extraction procedure (Chomczynski and Sacchi, 1987). Total RNAs were separated on a 1% agarose gel containing 6% formaldehyde and transferred to the Hybond N nylon membrane (Amerham Corp., Arlington Heights, IL). A Northern blot filter containing poly A-rich RNA from various mouse tissues was obtained from Clontech Laboratories (Palo Alto, CA). The RNA filters were hybridized and washed to remove the background. Hybridization was performed with a nick-translated fibulin-1 (MK24) (Pan et al., 1993), fibulin-2 (MK9), or human actin (American Type Culture Collection, Rockville, MD) cDNA probes under stringent conditions as described (Sambrook et al., 1989).

Expression Vector, Transfections, and Cell Culture

A full-length fibulin-2 cDNA clone (MK9, 4,377 bp in pBluescript SK-) was linearized at the unique BglII site in the 3'-untranslated region of the cDNA insert, and then blunt-ended by filling in using the Klenow fragment of DNA polymerase. The cDNA insert was released by digestion with NotI in the polylinker of the pBluescript vector. The eukaryotic Re/Cmv expression vector (Invitrogen, San Diego, CA) was linearized at the XbaI site in the polylinker region, blunted-ended, and then digested with NotI, whose site occurs 5' to the XbaI site in the polylinker region. The resulting vector was ligated with the cDNA insert, yielding an expression plasmid pCMK9 comprising 50 bp of the 5'-untranslated region, 3,663 bp of the entire coding region and 370 bp of the 3'-untranslated region.

Human embryonic kidney 293 cells (American Type Culture Collection) were cotransfected with pCMK9 and plasmid pSV-pac in order to generate stably transfected cell clones (Nischt et al., 1991). Those clones, which produced secreted fibulin-2, were identified by SDS electrophoresis of serum-free culture medium examined under reducing conditions. Serum-free culture medium was then prepared on a large scale (0.5-1 liter) by established protocols (Fox et al., 1991; Nischt et al., 1991).

Protein Purification

Fibulin-2 was precipitated from serum-free culture medium (~0.5 liter) by adding solid ammonium sulfate to 50% saturation (overnight, 4°C). The precipitate was then dissolved in ~5 ml of 0.15 M NaCl, 0.05 M Tris-HCl, pH 7.4, containing protease inhibitors and passed over a Sephacore CL-6B column (3 × 130 cm) equilibrated in the same buffer (Paulsson et al., 1987a). Pooled fractions containing the protein were subsequently dialyzed against 2 M urea, 0.02 M bis-Tris-propane-HCl, pH 6.5, 5 mM EDTA and chromatographed on a Mono Q column (HR 5/5; Pharmacia) which was eluted with a linear NaCl gradient (0.06 M NaCl, 35 ml) prepared in the same buffer. If a final purification step was required, chromatography on a Superose 6 column (HR 16/50; Pharmacia Inc.) in 0.2 M ammonium acetate, pH 6.8, was used. Samples were dissolved in neutral buffer and stored at -20°C. Reduction and alkylation in 6 M guanidine-HCl followed a procedure previously reported (Kluge et al., 1990).

Fibulin-1 (BM-90) was prepared either from a mouse tumor (Kluge et al., 1990) or obtained as a recombinant product based on cDNA encoding the splice variant D (Pan et al., 1993) following a protocol as outlined above (Sasaki, T., M.-L. Chu, and R. Timpl, unpublished data). Recombinant mouse nidogen (Fox et al., 1991) and human BM-40 (Nischt et al., 1991) were prepared as previously described. Laminin-nidogen complex and the heparan-sulfate-proteoglycan perlecain were purified from a mouse tumor (Paulsson et al., 1987a and b). Human plasma fibronectin (Behringwerke, Marburg Lahn, Germany) and vitronectin (Yatohgo et al., 1988) were obtained by chromatography on heparin-Sepharose.

Analytical Methods and Rotary Shadowing

PAGE (3-10% gradient gel) was used in the presence of SDS followed established protocols. Runs were calibrated with protein standards used in nonreduced or reduced form. Protein samples were hydrolyzed with 6 M HCl (16 h, 110°C) for the determination of amino acid composition and protein concentrations using an LC 3000 analyzer (Biotronik). Amino acid sequences were determined by a 473A gas-phase sequencer (Applied Biosystems, Inc., Foster City, CA) following the manufacturer's instructions. Rotary shadowing and EM of proteins followed previously described methods (Paulsson et al., 1987a and b).

Immunological Methods

Immunoconjugates using rabbits, ELISA, and radioimmuno-inhibition assays followed standard procedures (Timpl, 1982). Affinity-purified rabbit antibodies against mouse fibulin-1 (BM-90) were those described previously (Kluge et al., 1990). Most tissues used for indirect immunofluorescence were obtained from a 4-wk-old female BALB/c mouse. The skin specimen was isolated from the abdominal region of a 1-day-old BALB/c mouse. All tissue specimens were frozen by liquid nitrogen and cryosections (~6 μm) were prepared on a Reichert-Jung cryostat (Leica, Inc., Deerfield, IL). All specimens were fixed in acetone for 10 min at -20°C and washed in PBS, pH 7.2. Antibodies against fibulin-1 (1:20) and fibulin-2 (1:150) were diluted as indicated in PBS containing 1% ovalbumin. Normal rabbit serum (1:150) served as a negative control. Fluorescence labeling was performed with FITC-conjugated swine anti-rabbit immunoglobulins (DAKOAPATS, Copenhagen, Denmark). All the fluorescent specimens were mounted in 10% glycerol containing 1 mg/ml β-phenylenediamine (Johnson et al., 1982). Microscopy was carried out with a Axiphot fluorescence microscope (Zeiss, Oberkochen, FRG).
Results

Cloning and Sequence Analysis of Fibulin-2

Screening of a mouse fibroblast cDNA library with a human fibulin-1 cDNA probe under low stringency conditions yielded two groups of homologous cDNA clones. One group encoded two different splice variants of mouse fibulin-1 (Pan et al., 1993). The second group encoded a larger, novel protein referred to in the following discussion as fibulin-2. The largest fibulin-2 cDNA clone (MK9, 4.4 kb) was used to determine the whole nucleotide sequence (Fig. 1).

The nucleotide sequence of clone MK9 predicted an open reading frame of 3,633 bp, 50 bp of 5'-untranslated region, and 664 bp of 3'-untranslated region (Fig. 1). Applying the (-3, -1) rule (von Heijne, 1985), a 26-residue signal peptide and 1195 residues for the mature protein were predicted. Fibulin-2, therefore, exceeds the size of mouse fibulin-1 variant C (Pan et al., 1993) by 576 residues. The region of similarity between the two fibulins is restricted to the 3' half of fibulin-2 (60% nucleotide identity). The predicted amino acid sequence shows that fibulin-2 is rich in cysteine (107 residues), and contains four N-linked oligosaccharide acceptor sites scattered throughout the molecule (Fig. 1). A single RGD sequence (positions 395–397) suggests a cell-adhesive site. A highly acidic region (9 Glu, 1 Asp) is found at positions 246–255. A similar acidic sequence followed later by RGD has been described for bone sialoprotein (Oldberg et al., 1988).

Four smaller fibulin-2 cDNA clones were also partially sequenced. These clones (2.5–3.9 kb) showed a gap in the nucleotide sequence (positions 2175–2316) corresponding to the predicted subdomain IIb (Fig. 2), suggesting a modification by alternative splicing. Four fibulin-1 splice variants (A–D) have been described (Argraves et al., 1990; Pan et al., 1993) which differ at their 3' ends and the common point of deviation would correspond to nucleotide position 3669 in fibulin-2. The examination of 6 fibulin-2 cDNA clones encompassing this region, however, did not reveal any sequence difference.

Domain Structure and Comparison with Fibulin-1

The fibulin-2 sequence predicts a multidomain structure (Fig. 2). The NH2-terminal 408 residues (domain N) are unique to fibulin-2 and show no sequence similarity to fibulin-1 or to any other protein sequence found in the EMBL data bank. 22 cysteines are clustered in the first 150 residues of domain N, which suggests that the whole structure is folded into two different subdomains, Na (Cys-rich) and Nb (Cys-free). We could neither detect any compelling internal homology in the cysteine patterns of domain Na nor any similarity to cysteine arrays in other proteins.

The remaining structure of fibulin-2 is much more similar

Figure 1. Nucleotide sequence of fibulin-2 cDNA clone MK9 and deduced amino acid sequence. The signal peptidase cleavage site is indicated (v); amino acid numbering starts after this site. Full arrow heads denote the beginning and ending of various domains and subdomains (see Fig. 2). Asparagines identified as potential N-glycosylation sites are circled and an RGD sequence is boxed. These sequence data are available from EMBL/GenBank/DDBJ under accession number X75285.

Figure 2. Domain model of fibulin-2 (2) and comparison with that of fibulin-1 (1) starting with the NH2 termini at the left side. Diamonds in domain I indicate three motifs related to anaphylatoxins. Circles in domain II represent EGF-like repeats and those with a dot possess a consensus motif for calcium binding. The unique globular domain N consists of a Cys-rich (a) and a Cys-free (b) segment. The COOH-terminal domain III exists in fibulin-1 in four alternatives, A–D (amino acid numbers in brackets), while only one homolog to variant C has been detected in fibulin-2. The domain model for fibulin-1 is based on previous data (Argraves et al., 1990; Pan et al., 1993).
Figure 3. Sequence alignment of similar repeats in domains I and II of fibulin-2 and comparison with the sequence of mouse fibulin-1. The assignment of repeats is correlated to those in Figs. 1 and 2 and include in addition the single copy of domain III. The sequences shown on top are from fibulin-2 with substitutions found in fibulin-1 indicated underneath. Dashes indicate gaps introduced for optimal alignment of the two fibulin sequences. Asterisks on top indicate a calcium binding site (Rees et al., 1988; Selander et al., 1992), and all belong to the type II consensus motif (Handford et al., 1991).

Sequence comparison of those domains shared by fibulin-1 and -2 (Fig. 3) showed a low identity of 26% for domain I and required several gaps to be introduced for cysteine alignment. Identity was increased to 55% in domain II with all the cysteines and residues required as calcium ligands being conserved. Domain III showed 43% identity when compared to fibulin-1 variant C but no similarity to the corresponding variants B and D (see Fig. 2). In addition, comparison of the link regions failed to show any similarity. Taken together, the average identity is 43% for those regions common to both fibulin isoforms (666 residues).

**Recombinant Expression of Fibulin-2**

Several stable 293 cell clones were obtained after transfection with full-length fibulin-2 cDNA in an expression vector containing transcriptional control regions of the human cytomegalovirus. These 293-cell clones showed a single band in Northern blots similar in size to that of fibroblasts, and which was not detectable in the parent 293 cells. Examination of serum-free cell culture medium by SDS electrophoresis under reducing conditions revealed a major ~200-kD band unique to those clones and, occasionally, some smaller degradation products that blotted with an antiserum against fibulin-2 (data not shown). These findings were confirmed by radioimmunoassay of the media obtained from various clones (see below), which demonstrated 1-18 µg/ml of fibulin-2. Less than 0.02 µg/ml was detected in 293 cells.

A single clone (MK9-41) which showed high production and minimal degradation was used for large scale purification of fibulin-2. After molecular sieve chromatography of ammonium sulfate-precipitated material, the protein eluted in a distinct peak shortly after the void volume of a Sepharose CL-6B column. Some fibulin-2 was also detected in a peak emerging with the void volume and probably represents small amounts of aggregated protein. Fibulin-2 of >95% electrophoretic homogeneity was then obtained by Mono Q anion exchange chromatography, where the protein eluted in a broad range of the NaCl gradient (0.4-0.5 M). Reduced fibulin-2 consists of a single electrophoretic band with an apparent molecular mass of 195 kD (Fig. 4, lane 3). A major single band >400 kD was observed prior to reduction (Fig. 4, lane 4) indicating that fibulin-2 is secreted in the

Figure 4. Electrophoresis pattern of recombinant fibulin-2 in comparison to recombinant fibulin-1. Samples used were recombinant fibulin-2 (lanes 1 and 3) and recombinant fibulin-1 (lanes 2 and 4). They were analyzed under nonreducing conditions (lanes 1 and 2) or after reduction (lanes 3 and 4). Runs were calibrated with nonreduced (left margin) or reduced (right margin) globular proteins with migration position indicated by their molecular masses (kD).
form of a defined oligomer. Recombinant fibulin-1, however, consists of a single 85-kD band which shifts to a 105-kD migration position after reduction (Fig. 4, lanes 2 and 4) as previously observed for tissue-derived forms of the protein (Arggraves et al., 1989; Kluge et al., 1990).

In addition to the major 200-kD band, several other clones showed a distinct 160-kD band, which in some purified batches, even predominated. Several more distinct although minor bands (100-140 kD) could be detected occasionally and may have arisen during purification. These smaller variants were also connected into oligomers by disulfide bonds. Because these smaller fibulin-2 variants cannot be the products of mRNA splicing, they must have been generated by endogenous proteolysis.

**Structural and Immunological Properties**

Edman degradation of the fibulin-2 195-kD band demonstrated the NH2-terminal sequence VPWQDXTGA, in agreement with the signal peptidase cleavage site predicted from the cDNA sequence (Fig. 1). Finding the same NH2-terminal sequence as was found for the 160-kD band would indicate that proteolytic shortening starts from the COOH-terminal end. Rotary shadowing of disulfide-bonded fibulin-2 revealed particles of low contrast showing a characteristic three arm structure composed of thin rods (Fig. 5). The average length of the rods was 40-45 nm, but smaller rods were also noted which could represent artifacts of degradation or could reflect imperfect metal decoration. The connecting structure frequently appears as a globular domain. Smaller globular structures were seen occasionally at the free ends of the strands. We interpret this major structure as an oligomer of three fibulin-2 chains in which only a limited portion of the chains are required for association. Other particles of fibulin-2 appeared as dimers or tetramers, or occurred in large aggregates with an undefined structure.

A rabbit antiserum was raised against fibulin-2 which showed in ELISA a high titer for fibulin-2 and a 1,000-fold lower binding to fibulin-1 (Fig. 6). A similar low binding was observed for recombinant nidogen but no reaction occurred.
with laminin-nidogen complex, perlecan, BM-40, fibronectin, or vitronectin. In contrast, antisera or affinity-purified antibodies against tissue-derived fibulin-1 (Fig. 6) showed a distinct reaction with recombinant fibulin-1 but no reaction with fibulin-2. This suggests that the antisera should be able to differentiate between the two isoforms of fibulin in complex biological specimens.

In addition, the antiserum against fibulin-2 showed high titer in radioimmunoassay, allowing us to establish a sensitive inhibition test (IC$_{50}$ = 4 ng/ml) for the quantitative determination of the antigen (Fig. 7). Inhibition profiles with identical slopes produced by fibulin-2 and culture medium from fibulin-2 clones and fibroblasts indicate that the antigens present in the biological samples share the same epitopes (Timpl, 1982). Mouse serum, however, was only a weak inhibitor, indicating a fibulin-2 concentration of less than 20 ng/ml. The inhibition assay was specific because fibulin-1, even at 1,000-fold excess, showed no activity. The inhibitory activity of reduced and alkylated fibulin-2 was decreased to low levels indicating that most of the epitopes involved depend on an intact conformation.

Expression and Localization of the Fibulin Isoforms in Tissues

Initial studies were performed with cultured cells using Northern blots and radioimmunoassay determinations of proteins secreted in the culture medium (Fig. 7). Fibulin-2 was detected in four different mouse fibroblast media at an average concentration of 260 ± 130 ng/ml but was not detected in the medium of mouse teratocarcinoma cell line F9, parietal endoderm cells PYS-2, and B16F10 melanoma cells (<20 ng/ml). Northern blot analysis of total RNA from mouse fibroblasts showed hybridization to a broad band at the position of 28S ribosomal RNA (Fig. 8 A). This is consistent with the existence of at least two different mRNA transcripts due to the presence or absence of a single EGF-like repeat (Iy). Fibulin-2 mRNA was not expressed in F9 cells (data not shown) in contrast to the previous observation for fibulin-1 (Pan et al., 1993).

The expression of fibulin-2 was also examined by Northern blotting using poly A-rich RNA from various adult mouse tissues (Fig. 8 B). The fibulin-2 probe detected a 4.5-kb mRNA, in good agreement with the size of the full-length cDNA. However, the cDNA also detected another transcript of ~7.0 kb in some tissues. It is not clear whether or not the 7.0-kb band is transcribed from the same gene. The strongest hybridization was observed in heart tissue and much weaker signals were found in lung, liver, skeletal muscle, kidney, brain, spleen, and testis tissue. It was noted the 7-kb transcript was stronger than the 4.5-kb band in kidney and brain tissue. The tissue expression pattern was compared to that of fibulin-1 (Fig. 8 B) which is characterized by 2.3- and 2.7-kb transcripts (Argraves et al., 1990; Pan et al., 1993). Both fibulin-1 and -2 mRNAs were present at very high levels in heart tissue. However, more fibulin-1 mRNA than fibulin-2 mRNA was found in lung, testis, kidney, and brain tissue.

A comparative study of the tissue localization of the two isoforms of fibulin was performed by indirect immunofluorescence. Identical staining patterns were observed for skeletal muscle and heart tissue outlining the extracellular space that surrounds the muscle fibers (Fig. 9 a and b). In the cornea, both fibulin-1 and fibulin-2 are found along Bowman's and Descemet's membrane (Fig. 9 c). Staining for fibulin-1 was strong in the stromal compartment. In contrast, strong deposits of fibulin-2 could be detected in the squamous epithelium on top of Bowman's membrane, while only little staining was found in the stroma. Kidney tissue con-

Figure 8. Northern blots of RNA from mouse fibroblasts and tissues. (A) 10 £g of total RNA from mouse fibroblasts was probed with fibulin-2 cDNA clone MK9. (B) Northern blot analysis of poly A-enriched RNAs from mouse tissues. Each lane contained 2 £g of poly A-enriched RNA and was probed sequentially with fibulin-2 cDNA (MK9), fibulin-1 cDNA (MK24) (Pan et al., 1993), and human actin cDNA.
Figure 9. Immunofluorescence staining pattern of various mouse tissues by antisera specific for fibulin isoforms. Staining in row 1 was with affinity-purified anti-fibulin-1 and in row 2 with anti-fibulin-2. Two consecutive tissue sections are illustrated under a–f: (a) Skeletal muscle, (b) heart muscle, (c) cornea with Descemet's membrane on the left, (d) kidney showing a single glomerulus, (e) aorta in cross section, (f) skin with the epidermis on top and the subcutis starting at the bottom region. Similar tissue sections were also incubated with normal rabbit serum which yielded negative results except for a very weak staining of the epidermis (data not shown). Bars, 40 μm.

Pan et al. Structure and Expression of Fibulin-2


**Discussion**

Sequence analysis, recombinant expression, and immunological assays demonstrate that fibulin-2 is a new extracellular matrix protein. The closest relative seems to be fibulin-1, with 43% sequence identity between the domains shared by the two proteins. This level of identity is in the range observed for other protein isoforms like the diverse laminin chains, which also contain multiple EGF-like repeats (Engel, 1993). We suggest classification of the fibulins into a novel protein family and suggest use of Arabic numbers for their designation as used with the thrombospondins (Bornstein, 1992). Many consecutive EGF-like repeats with calcium-binding motifs are the hallmark of fibrillin (Lee et al., 1991; Maslen et al., 1991) and TGF-β1 binding protein (Kanzaki et al., 1990) but are less abundant in nidogen (Mann et al., 1989) and EGF precursor (Scott et al., 1983). The multiple repeats in these proteins, however, are joined to domains different from those found in the fibulins. In addition, several Drosophila and C.elegans proteins (notch, lin-12, and others) contain tandem arranged EGF-like repeats and play a role in development (Kelley et al., 1987; Yochem and Greenwald, 1989; Bork, 1991). The common structural motifs suggest that these proteins may have originated from common ancestral precursors by exon shuffling and together represent a superfamily.

EM of recombinant fibulin-2 demonstrates a trimeric rod structure connected by disulfide bonds. A similar structure but with large, calcium-dependent globular domains at the distal ends was described for thrombospondin-1 (Lawler et al., 1985). The two proteins show only a low similarity in sequence and domain structure (Lawler and Hynes, 1986). It is not presently known whether or not other isoforms of thrombospondin (Bornstein, 1992) have similar structures. In contrast, fibulin-1 has the shape of a single rod of ~30 nm length (Kluge, 1990). The rods of fibulin-2 are longer (40–45 nm) and very likely include the 11 EGF-like repeats of domain II. The predicted length for a row of such repeats is about 25 nm (Engel, 1989), suggesting that other domains (Nb, I and III) are included in the rod structure. The reduced chain of fibulin-2 and a truncated 160-kD form share the same NH₂-terminal sequence, thus indicating that domain Na contributes the disulfide bonds for the connection of the rods and is part of the central globular domain. A disulfide-linked NH₂-terminal connection has also been identified for thrombospondin-1.

The molecular mass of the fibulin-2 chain, based on the sequence and assuming substitutions with typical N-linked oligosaccharides, was calculated to be ~142 kD. The mass determined from electrophoretic migration, however, was 195 kD. A similar difference between calculated (82 kD) and observed (105 kD) molecular mass was found for fibulin-1, indicating either substitution with unusually large oligosaccharides, or an anomalous electrophoretic mobility common to both fibulins, which should be further studied by ultracentrifugation. Calcium binding has been shown only for fibulin-1 (Argraves et al., 1990; Kluge et al., 1990), but the number of occupied sites and their affinities are not yet known. The binding of fibulin-1 to laminin or nidogen is dependent on calcium and completely abolished by EDTA (Pan et al., 1993). Preliminary studies with fibulin-2 show that its binding to fibronectin and some other ligands is also calcium dependent (Sasaki, T., and R. Timpl, unpublished results), suggesting that some of the putative calcium-binding motifs in domain II of fibulin-2 are active in providing calcium coordination sites.

A low immunological cross-reactivity was observed between the two fibulins which is presumably accounted for by the relatively low sequence identity and further differences in the domain structure. This allows us to differentiate the two proteins by radioimmuno- and other immunological assays in various biological samples. The serum concentration of fibulin-2 is low and comparable with those of most other extracellular matrix proteins (Risteli and Risteli, 1987). A serum concentration at least 1,000-fold higher (20–30 µg/ml) has been found for fibulin-1 (Argraves et al., 1990; Kluge et al., 1990) suggesting different cellular origins of the circulating fibulin isoforms. We have shown by Northern blots that liver cells are an unlikely source of serum fibulin-1, although hepatocytes are the main producers of serum fibronectin (Hynes, 1990).

Fibroblasts are the only cells examined so far that produce both isoforms of fibulins as shown in this and previous studies (Argraves et al., 1990; Kluge et al., 1990). Fibulin-2 was not detected by radioimmunoassay in several mouse tumor cell lines, but a substantial secretion of fibulin-1 (100–460 ng/ml) was observed (Kluge et al., 1990). An overlapping, but not identical, tissue expression pattern of both fibulins was also observed by Northern analyses of RNAs from cultured cells and tissues. It appears that the expression of fibulin-2 is more restricted, and the regulation of the expression of the two fibulin isoforms is not strictly coordinated. Of particular interest is the high expression of both fibulin mRNAs in heart tissue. Fibulin-1 has been shown to be enriched in the endocardial cushion tissue during heart development (Spence et al., 1992; Zhang et al., 1993). The expression of fibulin-2 in developing heart tissue remains to be investigated.

Differences are noted in the tissue localization of the two fibulins by indirect immunofluorescence. Fibulin-2, but not fibulin-1, is detected in the keratinocyte cell layer of the epidermis and hairs, the epithelial cell layer of cornea, the aortic intima, and around small vessels in kidney and liver. However, staining of fibulin-1 seems to be much stronger than fibulin-2 in the corneal stroma and glomerular basement membranes. Both isoforms colocalize in several other anatomical compartments such as the perimysium of skeletal muscle, the matrix surrounding myocytes, the renal mesangium, and the two basement membranes of the cornea, but the latter interpretation still needs confirmation by immunoelectronmicroscopy. Together the data demonstrate that fibulin-2 is a typical extracellular matrix protein, which can be a component of both basement membranes and other connective tissues.

We thank Dr. Karlheinz Mann for sequence analysis, Mrs. Hanna Wiedermann for EM, Mrs. Mischa Reiter and Mrs. Marlene Grüne for assistance in immunological studies, and Dr. John Gartland for critical reading of the manuscript. This work was supported by grants from the National Institutes of Health (AR-38912, AR-38923, GM-48532) and by the Deutsche Forschungsgemeinschaft (Ti 95/7-2).

Received for publication 18 August 1993.
References
Argraves, W. S., K. Dickerson, W. H. Burgess, and E. Rusolakhi. 1989. Fibulin, a novel protein that interacts with the fibronectin receptor $\beta$ subunit cytoplasmic domain. Cell. 58:623–629.
Argraves, W. S., H. Tran, W. H. Burgess, and K. Dickerson. 1990. Fibulin is an extracellular matrix and plasma glycoprotein with repeated domain structure. J. Biol. Chem. 265:3115–3126.
Balbona, K., H. Tran, S. Godyna, K. C. Ingham, D. K. Strickland, and W. S. Argraves. 1992. Fibulin binds to itself and to the carboxy-terminal heparin-binding region of fibronectin. J. Biol. Chem. 267:20120–20125.
Baron, M., G. D. Johnson, and D. Campbell. 1991. Protein modules. Trends Biochem. Sci. 16:13–17.
Beck, K., I. Hunter, and J. Engel. 1990. Structure and function of laminin: anatomy of a multidomain glycoprotein. FASEB (Fed. Am. Soc. Exp. Biol.) J. 4:148–160.
Belt, K. T., M. C. Carroll, and R. R. Porter. 1984. The structural basis of the multiple forms of human complement component C4. Cell. 36:907–914.
Bork, P. (1991). Shuffled domains in extracellular proteins. Trends Biochem. Sci. Lett. 286:67–54.
Bornstein, P. 1992. Thrombospondins: structure and regulation of expression. FASEB (Fed. Am. Soc. Exp. Biol.) J. 6:3290–3299.
Chomczynski, P., and N. Sacchi. 1987. Single-step method of RNA isolation by acid guanidium-phenol-chloroform extraction. Anal. Biochem. 162:156–159.
de Brujin, M. H. L., and G. H. Fey. 1985. Human complement component C3: cDNA coding sequence and derived primary structure. Proc. Natl. Acad. Sci. USA. 82:708–712.
Dietz, H. C., R. A. Oldberg, A. B. Franzen, and D. Heinegard. 1988. The primary structure of a cell-binding bone sialoprotein. J. Biol. Chem. 263:19430–19432.
Pan et al. 1989. The structure of human platelet thrombospondin. X. J. Biol. Chem. 264:16897–16904.
Rees, D. J. G., J. M. Jones, P. A. Handford, S. J. Walter, M. P. Esonouf, K. J. Smith, and G. G. Brownlee. 1988. The role of $\beta$-hydroxysterapate and adjacent carbohydrate residues in the first EGF domain of human factor IX. EMBO (Eur. Mol. Biol. Organ.) J. 7:2003–2061.
Risteli, L., and J. Risteli. 1987. Analysis of extracellular matrix proteins in biological fluids. Methods Enzymol. 145:391–411.
Sambrook, J., E. F. Fritsch, and T. Maniatis. 1989. Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
Sanger, F., S. Nicklen, and A. R. Coulson. 1977. DNA sequencing with chain-terminating inhibitors. Proc. Natl. Acad. Sci. USA. 74:5463–5467.
Scott, J., M. Urdea, M. Quirigo, R. Sanchez-Pescador, N. Forj, M. Selby, W. J. Rutter, and G. I. Bell. 1983. Structure of a mouse submaxillary messenger RNA encoding epidermal growth factor and seven related proteins. Science (Wash. DC). 221:236–240.
Sundler-Runehagen, M., M. Ullgren, E. Persson, O. Telemann, J. Stenflo, and T. Persson. 1989. Primary structure of bovine factor X and a model for the calcium binding domain. J. Mol. Biol. 213:279–313.
van Heijne, G. 1985. Signal sequences. The limits of variation. J. Mol. Biol. 184:99–105.
Wetsel, R. A., R. T. Ogata, and B. F. Tack. 1987. Primary structure of the fifth component of murine complement. Cell. 53:555–564.
Yochem, J., and I. Greenwald. 1989. Glp-I and lin-12, genes implicated in dissector cell activity in C. elegans, encode similar transmembrane proteins. Cell. 59:325–334.
Topouzas, F. Rama, and D. W. Hollister. 1991. Linkage of Marfan syndrome and a phenotypically related disorder to different fibrillin genes. Nature (Lond.) 352:330–334.
Mayer, U., R. Timpl, M. L. Wu, B. L. Chen, T. Pan, D. Conway, and M.-L. Chu. 1989. Amino acid sequence of mouse nidogen, a multidomain basement membrane protein with binding activity for laminin, collagen IV and cells. EMBO (Eur. Mol. Biol. Organ.) J. 8:6531–6537.
Mayer, U., R. Timpl, M.-L. Chu, and P. Ekblom. 1993. The extracellular matrix glycoproteins BM-90 and tenascin are expressed in the mesenchymal-mesenchymal conversion in the embryonic mouse heart. Differentiation. 52:211–220.

Pan et al. Structure and Expression of Fibulin-2 1277